In-Cell-Art is a biopharmaceutical company

specializing in the preclinical and pharmaceutical development of nanocarriers named Nanotaxi® for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organized on a nanometric scale, which enables them to cross the cell barrier efficiently and safely.

More From Us

Latest news

In-Cell-Art's Japanese collaborator Cosmo Bio published in BIO Clinica an article featuring two rare and high quality Amyotrophic Lateral Sclerosis diagnostic antibodies (GPNMB, ITIH4) discovered by In-Cell-Art's ICANtibodies technology platform

(BIO Clinica Vol.5 No.1. 2016)
July 6th

Activities

  • ICAntibodies™

    ICAntibodies™, the discovery of next-generation therapeutic antibodies

  • ICAvaccine

    Production of the new "solution" for DNA or RNA vaccines

  • ICAfectin®

    The “solutions” for your all transfections

  • ICAchem

    Get the molecule you want with our chemical synthesis platform

  • ICAtherapeutics

    mRNA Destination™, a novel technology for therapeutic protein production